☆ 4.7 Article

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium

Rakan Nasreddine et al.

Summary: This study aimed to evaluate the efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine in a real-world setting. The results showed that both regimens were effective and well-tolerated for both treatment-naive and treatment-experienced patients. The study also found that these regimens may lead to a slight increase in weight.

HIV MEDICINE (2023)

Add to Collection

Article Infectious Diseases

Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting

Colin Deschanvres et al.

Summary: Maintenance ART with dolutegravir-based dual regimens has shown efficacy in HIV-1infected subjects, but real-life data are limited. In this study, virological failure and resistance-associated mutations were assessed in dolutegravir maintenance regimens. Results indicated that careful virological screening is essential before switching to dolutegravir maintenance regimens in virologically suppressed patients.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Specific mutations in the HIV-1 G-tract of the 3′-polypurine tract cause resistance to integrase strand transfer inhibitors

Atsuko Hachiya et al.

Summary: This study investigated the specific mutations in the G-tract of the 3'-PPT that confer resistance to integrase strand transfer inhibitors (INSTIs). The results showed that mutations at the second and fifth positions increased INSTI resistance, likely through a non-competitive mechanism of inhibition.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study

Roberta Gagliardini et al.

Summary: This study evaluated the impact of resistance mutations on the efficacy of dolutegravir-based two-drug regimens. The results showed that the dolutegravir-based two-drug regimens had high virological efficacy and durability, but past resistance increased the risk of virological failure.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2022)

Add to Collection

Article Immunology

Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1

Murat Sayan et al.

Summary: This study evaluated the mutations associated with INSTI resistance in naive HIV-1 infected patients. The results showed that INSTI resistance was not detected in patients who had not received antiretroviral treatment. However, a significant proportion of patients who had received INSTI treatment showed INSTI resistance mutations. The prevalence of drug resistance mutations varied among different drug classes.

CURRENT HIV RESEARCH (2022)

Add to Collection

Article Immunology

High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy

Kristi Huik et al.

Summary: This study investigated an individual with INSTI mutations and found that T97A-containing HIV variants emerged from a small number of viral lineages. The T97A mutation, when combined with primary INSTI resistance mutations, showed strong selective advantage. These T97A-containing variants spread through replication and recombination and persisted for months after discontinuing dolutegravir, which has important implications for its global rollout.

AIDS (2022)

Add to Collection

Article Virology

Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration

Clemence Richetta et al.

Summary: This study discovered a drug-resistant virus to strand-transfer inhibitors with a mutation in the 3'-PPT region instead of the integrase gene. This mutation altered the reverse transcription process, leading to the accumulation of 1-LTR circular structures instead of linear DNA. The accumulation of 1-LTR circles enabled viral replication without integration of the viral genome.

JOURNAL OF VIROLOGY (2022)

Add to Collection

Article Infectious Diseases

Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice

Daniele Armenia et al.

Summary: The study evaluated the virological response and resistance profile in cART-experienced HIV-1 patients initiating a dual therapy with DTG and bDRV for the first time. The results showed a high rate of virological control with this dual therapy regimen in highly treatment-experienced patients, and the selection of further resistance in non-responding patients was rare.

HIV MEDICINE (2021)

Add to Collection

Article Immunology

Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons

Alexander J. Bailey et al.

Summary: A systematic review found a low prevalence of INSTI resistance in HIV-1-infected adults who have not received INSTI treatment, with most cases being common polymorphic accessory mutations.

AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)

Add to Collection

Article Immunology

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy G. Cutrell et al.

Summary: In long-acting cabotegravir (CAB) and rilpivirine (RPV) intramuscular dosing, factors associated with virologic failure at Week 48 include proviral RPV resistance-associated mutations, HIV-1 subtype A6/A1, higher BMI, and lower RPV trough concentrations. The presence of at least two of these baseline factors is linked to increased risk of virologic failure.

AIDS (2021)

Add to Collection

Review Infectious Diseases

HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance

Nokuzola Mbhele et al.

Summary: Antiretroviral therapy is crucial in controlling the HIV epidemic, with integrase strand transfer inhibitors (INSTIs) becoming more common. INSTIs have a higher genetic barrier to resistance, with DTG showing even higher resistance barriers and CAB being used as the first long-acting agent in HIV-1 treatment.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Add to Collection

Article Infectious Diseases

Prevalence of genotypic baseline risk factors for cabotegravir plus rilpivirine failure among ARV-naive patients

Charlotte Charpentier et al.

Summary: The study found that HIV-1 subtypes A6/A1 and the presence of rilpivirine RAMs are baseline risk factors associated with virological failure of cabotegravir+rilpivirine dual therapy among ARV-naive patients. Among large sequence databases, approximately 10.1% of patients would be ineligible for cabotegravir+rilpivirine dual therapy due to the presence of rilpivirine-resistant viruses and HIV-1 subtype A6/A1 sequences.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey

Anne-Genevieve Marcelin et al.

Summary: A study was conducted on 1104 patients failing any INSTI-containing 2DR or 3DR regimens. Factors associated with the emergence of integrase resistance mutations at failure included high viral load, non-B subtype, low genotypic sensitivity score, and the use of dolutegravir. No significant difference was found between patients receiving a 2DR or a 3DR.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance

Philip L. Tzou et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Review Immunology

Emergent Resistance to Dolutegravir Among INSTI-Naive Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases

Muge Cevik et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir plus Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

Jean van Wyk et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)

Add to Collection

Article Virology

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings

Daniele Armenia et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Add to Collection

Article Infectious Diseases

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients

Anne-Genevieve Marcelin et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

Kristina M. Brooks et al.

PHARMACOTHERAPY (2019)

Add to Collection

Review Infectious Diseases

A systematic review of the genetic mechanisms of dolutegravir resistance

Soo-Yon Rhee et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Immunology

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Michael Aboud et al.

LANCET HIV (2019)

Add to Collection

Review Infectious Diseases

Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors

Li-Li Yang et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)

Add to Collection

Article Immunology

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Laurent Hocqueloux et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort

S. Modica et al.

HIV MEDICINE (2019)

Add to Collection

Editorial Material Immunology

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance

N. Ahmed et al.

OPEN FORUM INFECTIOUS DISEASES (2019)

Add to Collection

Article Immunology

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

Ingeborg E. A. Wijting et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Jomy M. George et al.

OPEN FORUM INFECTIOUS DISEASES (2018)

Add to Collection

Letter Infectious Diseases

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

P. Gantner et al.

HIV MEDICINE (2017)

Add to Collection

Review Virology

HIV drug resistance against strand transfer integrase inhibitors

Kaitlin Anstett et al.

RETROVIROLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

Amedeo F. Capetti et al.

PLOS ONE (2016)

Add to Collection

Review Pharmacology & Pharmacy

HIV integrase inhibitors: a new era in the treatment of HIV

Jose Luis Blanco et al.

EXPERT OPINION ON PHARMACOTHERAPY (2015)

Add to Collection

Review Pharmacology & Pharmacy

Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection

R. Chris Rathbun et al.

ANNALS OF PHARMACOTHERAPY (2014)

Add to Collection

Letter Infectious Diseases

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

S. Reigadas et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)

Add to Collection

Article Medicine, General & Internal

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn et al.

LANCET (2013)

Add to Collection

Article Infectious Diseases

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

Francois Raffi et al.

LANCET INFECTIOUS DISEASES (2013)

Add to Collection

Article Virology

Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase

Richard E. Myers et al.

JOURNAL OF VIROLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.